5 结果
BACKGROUND OF THE INVENTION
Many clinical disorders are characterized as etiologically diverse, thereby complicating diagnosis and treatment. Diabetes mellitus, the most prevalent of the endocrine diseases, is one example. The disease, which is characterized by metabolic abnormalities and by
FIELD OF THE INVENTION
The present invention relates to RNA editing polypeptides and methods for screening mRNA for editing.
BACKGROUND OF THE INVENTION
Apolipoprotein B occurs naturally in two forms, apo-B100 and apo-B48, both encoded by the same gene. Apo-B100, a 550 KD protein, is the major
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to the identification of new muteins of fibroblast growth factor 21 that have reduced deamidation when compared to wild type fibroblast growth factor 21.
2. Description of the Related Art
Fibroblast growth factors
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to the identification of new muteins of fibroblast growth factor 21 that have reduced O-linked glycosylation when expressed in yeast.
2. Description of the Related Art
Fibroblast growth factors are large polypeptides
BACKGROUND
1. Technical Field
This document relates to butyrylcholinesterases (BChE) having an enhanced ability to hydrolyze acyl ghrelin as well as methods and materials for treating obesity and aggression. For example, this document provides nucleic acids encoding a butyrylcholinesterase having an